Chinanews client, Beijing, April 13th (Reporter Zhang Ni) On the 12th, Zhejiang Pharmaceutical Equipment Procurement Center issued the "Notice on the Evaluation Results of Medical Prices and Untrustworthy Levels of Recruitment and Procurement in Our Province (2021 Phase 1)", disclosing The result of the first case of severely dishonest enterprise being punished.
Image source: webpage screenshot
According to the relevant facts disclosed in the judgment of the local court, the Lugua Polypeptide Injection of a listed pharmaceutical company was involved in commercial bribery in Zhejiang Province with a large amount of kickbacks. According to the medical price and bidding procurement system, the company was established in Zhejiang Province. The price of the centralized medical procurement market and the level of untrustworthy recruitment were assessed as "serious", and online trading of the company's Lugua Polypeptide Injection in Zhejiang Province was suspended.
It is reported that Zhejiang Province has also carried out credit evaluations in accordance with procedures for other pharmaceutical companies with rebate problems, and some pharmaceutical companies have taken measures such as proactive price reductions to restore credit.
In August 2020, the National Medical Insurance Administration launched the construction of a medical price and credit evaluation system, and gave rebates and other outstanding issues in the medical field to give play to the guiding and standardizing role of the centralized procurement market for medical products, and promote the return of reasonable prices of medical products.
Zhejiang Province notified the credit evaluation results of a company's Lugua Polypeptide Injection and suspended online transactions. This is the country's first governance case whose credit evaluation has reached a "serious" rating, marking that the credit evaluation system has entered a new stage of substantive effects.
According to reports, the National Medical Insurance Bureau will organize provincial medical security departments and centralized medical procurement agencies to accelerate the implementation of the credit evaluation system across the country.
At the same time, in response to the recently exposed medical companies’ excessively high sales costs and false expense accounting, and other issues that are contrary to honest operation and fair pricing, we continue to study and improve the credit evaluation system, strengthen the deterrent effect, and promote the fairness, reasonableness, and honesty of pharmaceutical companies. , Set prices based on the principle of quality and price, and resolutely safeguard the interests of the people.
(Finish)